Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.

Literature DB >> 23292179

Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.

Ryoko Horikoshi, Tetsu Akimoto, Makoto Inoue, Yoshiyuki Morishita, Eiji Kusano.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23292179 DOI： 10.1007/s10157-012-0763-7

Source DB: PubMed Journal: Clin Exp Nephrol ISSN： 1342-1751 Impact factor: 2.801

× No keyword cloud information.

5 in total

Review 1. Managing gout: how is it different in patients with chronic kidney disease?

Authors: Hossam El-Zawawy; Brian F Mandell
Journal: Cleve Clin J Med Date: 2010-12 Impact factor: 2.321

2. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.

Authors: Walead Latif; Angelo Karaboyas; Lin Tong; James F Winchester; Charlotte J Arrington; Ronald L Pisoni; Mark R Marshall; Werner Kleophas; Nathan W Levin; Ananda Sen; Bruce M Robinson; Rajiv Saran
Journal: Clin J Am Soc Nephrol Date: 2011-08-25 Impact factor: 8.237

3. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.

Authors: Tatsuo Hosoya; Hosoya Tatsuo; Iwao Ohno; Ohno Iwao
Journal: J Clin Rheumatol Date: 2011-06 Impact factor: 3.517

4. Japanese guideline for the management of hyperuricemia and gout: second edition.

Authors: Hisashi Yamanaka
Journal: Nucleosides Nucleotides Nucleic Acids Date: 2011-12 Impact factor: 1.381

5. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.

Authors: Hidetoshi Tsuda; Noritaka Kawada; Jun-ya Kaimori; Harumi Kitamura; Toshiki Moriyama; Hiromi Rakugi; Shiro Takahara; Yoshitaka Isaka
Journal: Biochem Biophys Res Commun Date: 2012-09-17 Impact factor: 3.575

5 in total

7 in total

Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.

Review 1. Managing gout: how is it different in patients with chronic kidney disease?

2. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.

3. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.

4. Japanese guideline for the management of hyperuricemia and gout: second edition.

5. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.

1. Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis.

Review 2. Urate-lowering therapy: current options and future prospects for elderly patients with gout.

3. Management of Gout and Hyperuricemia in CKD.

4. Association of Serum Uric Acid Concentration and Its Change with Cardiovascular Death and All-Cause Mortality.

5. Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report.

6. Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.

7. Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient.